Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6909006 | 1.00 | KIF11 (0.55) | KIF11 | |
| SCHEMBL18599373 | 0.98 | KIF11 (0.57) | KIF11 | |
| SCHEMBL10418791 | 0.87 | KIF11 (0.47) | KIF11 | |
| Trifluoroacetamide SCHEMBL28040960 | 0.85 | KIF11 (0.48) | KIF11 | |
| SCHEMBL11708407 | 0.85 | KIF11 (0.38) | KIF11 | |
| SCHEMBL9106215 | 0.84 | KIF11 (0.63) | KIF11 | |
| SCHEMBL19154882 | 0.83 | SIRT2 (0.50) | KIF11 | |
| SCHEMBL11295432 | 0.83 | KIF11 (0.37) | KIF11 | |
| SCHEMBL11705896 | 0.83 | KIF11 (0.37) | KIF11 | |
| SCHEMBL11615917 | 0.83 | KIF11 (0.37) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7495 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | claimed |
| WO-2009018332-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1814994-A2 | APPARATUS AND SYSTEM HAVING DRY GENE SILENCING COMPOSITIONS | Dharmacon, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006071410-A2 | APPARATUS AND SYSTEM HAVING DRY GENE SILENCING COMPOSITIONS | DHARMACON, INC. (US) | 2006-07-06 | — | — | WO | claimed |
| US-20060115461-A1 | Apparatus and system having dry gene silencing compositions | DHARMACON, INC. | 2006-06-01 | — | — | US | claimed |
| US-12042510-B2 | Modulators of IRF4 expression | IONIS PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12042509-B2 | Prekallikrein-modulating compositions and methods of use thereof | ADARX PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-12042508-B2 | Antisense compounds targeting genes associated with cystic fibrosis | ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240238326-A1 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT | BIOGEN MA INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3770258-B1 | MODULATION OF UBE3A-ATS EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-1999001579-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998049348-A1 | OLIGONUCLEOTIDES FOR ENHANCED BIOAVAILABILITY | ISIS PHARMACEUTICALS, INC. (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998045314-A1 | COMPOSITION AND METHOD FOR TREATMENT OF CMV INFECTIONS | ISIS PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| US-5801154-A | Antisense oligonucleotide modulation of multidrug resistance-associated protein | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1998029124-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| WO-1998027425-A1 | LARGE-SCALE PURIFICATION OF FULL LENGTH OLIGONUCLEOTIDES BY SOLID-LIQUID AFFINITY EXTRACTION | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0716604-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1996-06-19 | — | — | EP | disclosed |
| WO-1995006474-A1 | THIOL-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |